FUSION PROTEINS FOR HALF-LIFE EXTENSION - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 102

59. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al.
(2010) Chemical generation of bispecific antibodies. Proc.
Natl. Acad. Sci. USA 107(52), 22611-22616.
60. Buscaglia CA, Alfonso J, Campetella O, Frasch AC. (1999)
Tandem amino acid repeats from Trypanosoma cruzi shed
antigens increase the half-life of proteins in blood. Blood 93
(6), 2025-2032.
61. Alvarez P, Buscaglia CA, Campetella O. (2004) Improving
protein pharmacokinetics by genetic fusion to simple amino
acid sequences. J. Biol. Chem. 279(5), 3375-3381.
62. Schlapschy M, Theobald I, Mack H, Schottelius M, Wester
H-J, Skerra A. (2007) Fusion of a recombinant antibody
fragment with a homo-amino-acid polymer: effects on bio-
physical properties and prolonged plasma half-life. Protein
Eng. Des. Sel. 20(6), 273-284.
63. Schellenberger V, Wang C-W, Geething NC, Spink BJ,
Campbell A, To W, et al. (2009) A recombinant polypeptide
extends the in vivo half-life of peptides and proteins in a
tunable manner. Nat. Biotechnol 27(12), 1186-1190.
64. Geething NC, To W, Spink BJ, Scholle MD, Wang C, Yin Y,
et al. (2010) Gcg-XTEN: an improved glucagon capable of
preventing hypoglycemia without increasing baseline blood
glucose. PLoS ONE 5(4), e10175.
65. Egrie JC, Browne JK. (2001) Development and characteriza-
tion of novel erythropoiesis stimulating protein (NESP). Br. J.
Cancer 84(Suppl. 1), 3-10.
66. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ,
Boime I. (1992) Design of a long-acting follitropin agonist by
fusing the C-terminal sequence of the chorionic gonadotropin
beta subunit to the follitropin beta subunit. Proc. Natl. Acad.
Sci. USA 89(10), 4304-4308.
67. Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E. (2010)
Designing a long-acting human growth hormone (hGH) by
fusing the carboxyl-terminal peptide of human chorionic
gonadotropin beta-subunit to the coding sequence of hGH.
Endocrinology 151(9), 4410-4417.
68. Fares F, Havron A, Fima E. (2011) Designing a long acting
erythropoietin by fusing three carboxyl-terminal peptides of
human chorionic gonadotropin b subunit to the N-terminal
and C-terminal coding sequence. Int. J. Cell Biol. 2011,
275063.

69. Xu J, Tan L, Goodrum KJ, Kieliszewski MJ. (2007) High-
yields and extended serum half-life of human interferon
alpha2b expressed in tobacco cells as arabinogalactan-protein
fusions. Biotechnol. Bioeng. 97(5), 997-1008.
70. Xu J, Okada S, Tan L, Goodrum KJ, Kopchick JJ, Kieliszewski
MJ. (2010) Human growth hormone expressed in tobacco cells
as an arabinogalactan-protein fusion glycoprotein has a pro-
longed serum life. Transgenic Res. 19(5), 849-867.
71. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton
LA. (2006) A thermally responsive biopolymer for intra-
articular drug delivery. J. Control. Release 115(2), 175-182.
72. Shamji MF, Betre H, Kraus VB, Chen J, Chilkoti A, Pichika R,
et al. (2007) Development and characterization of a fusion
protein between thermally responsive elastin-like polypeptide
and interleukin-1 receptor antagonist: sustained release of a
local antiinflammatory therapeutic. Arthritis Rheum. 56(11),
3650-3661.
73. Bidwell GL3rd, Raucher D. (2010) Cell penetrating elastin-
like polypeptides for therapeutic peptide delivery. Adv. Drug
Deliv. Rev. 62(15), 1486-1496.
74. Huang Y-S, Wen X-F, Wu Y-L, Wang Y-F, Fan M, Yang Z-Y,
et al. (2010) Engineering a pharmacologically superior form
of granulocyte-colony-stimulating factor by fusion with
gelatin-like-protein polymer. Eur. J. Pharm. Biopharm.
74(3), 435-441.
75. Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C,
Touvay C, et al. (2007) A ligand-receptor fusion of growth
hormone forms a dimer and is a potent long-acting agonist.
Nat. Med. 13(9), 1108-1113.
76. Ferrandis E, Pradhananga SL, Touvay C, Kinoshita C, Wil-
kinson IR, Stafford K, et al. (2010) Immunogenicity, toxicol-
ogy, pharmacokinetics and pharmacodynamics of growth
hormone ligand-receptor fusions. Clin. Sci. 119(11), 483-491.
77. Adams G, Vessillier S, Dreja H, Chernajovsky Y. (2003)
Targeting cytokines to inflammation sites. Nat. Biotechnol.
21(11), 1314-1320.
78. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M,
Perretti M, et al. (2012) Molecular engineering of short
half-life small peptides (VIP, a MSH and g 3 MSH) fused to
latency-associated peptide results in improved anti-
inflammatory therapeutics. Ann. Rheum. Dis. 71(1), 143-149.